Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Atara Biotherapeutics ( (ATRA) ) is now available.
On December 30, 2025, Atara Biotherapeutics amended its commercialization agreement with Pierre Fabre Medicament, reducing potential regulatory milestone payments tied to FDA approval of a BLA for tab-cel from $40 million to $31 million in exchange for the opportunity to earn an additional $15 million milestone based on achieving a specified commercial milestone. The revised structure adjusts the balance between regulatory and commercial incentives, potentially aligning Pierre Fabre’s financial commitments more closely with tab-cel’s market performance and affecting the timing and composition of future milestone revenues for Atara.
The most recent analyst rating on (ATRA) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Atara Biotherapeutics stock, see the ATRA Stock Forecast page.
Spark’s Take on ATRA Stock
According to Spark, TipRanks’ AI Analyst, ATRA is a Neutral.
Atara Biotherapeutics’ overall stock score is primarily impacted by its financial instability and recent corporate restructuring. While technical indicators are positive, suggesting potential short-term gains, the company’s financial challenges and workforce reduction raise concerns about its long-term stability.
To see Spark’s full report on ATRA stock, click here.
More about Atara Biotherapeutics
Atara Biotherapeutics, Inc. is a biotechnology company focused on developing innovative cell-based therapies, including its lead candidate tab-cel, targeting serious diseases with significant unmet medical need.
Average Trading Volume: 65,926
Technical Sentiment Signal: Sell
Current Market Cap: $130.4M
For a thorough assessment of ATRA stock, go to TipRanks’ Stock Analysis page.